abcdefghijklmn
opqrstuvwxyz
Test Menu
Test Change Details
Allergy & Immunology
Cardiology & Coagulation
Dermatopathology
Endocrinology
Gastroenterology
Genetics
Hepatology
Infectious Disease
Microbiology
Nephrology
Neurology
Oncology
Pathology
Pediatrics
Rheumatology
Toxicology
Urology
Women's Health
34459: Acetylcholine Receptor Blocking Antibody Print View
Acetylcholine Rec Bloc Ab     % of inhibition 

PRIMARY
1 Serum 1 (0.5) mL   Room Temperature - 14 Day(s)/Refrigerated - 14 Day(s)/Frozen - 30 Day(s)  
ALTERNATE

Myasthenia Gravis (MG) is an autoimmune neuromuscular disorder characterized by muscle weakness, most commonly due to autoantibody- mediated loss of functional acetylcholine receptors (AChR) in the neuromuscular junction. AChR binding autoantibodies are diagnostic of MG, and are found in 85-90% of MG patients. AChR blocking autoantibodies prevent interaction of binding antibodies with the AChR. Fewer than 1% of patients have blocking antibodies without binding antibodies. Blocking antibodies are present in about 50% of patients with MG, but are rare in other conditions. Therefore, blocking antibodies have utility in ruling out a possible false positive binding assay and detecting the rare patient without AChR binding antibodies.
Setup Schedule
Sunday, Tuesday, Thursday

Reported (Analytical Time)
3 days

CPT Code
83519

The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

Notes
Transport Temperature: Room temperature Methodology: Radioimmunoassay Reject Criteria: Microbially contaminated; gross hemolysis; grossly lipemic






1996 - 2017 Quest Diagnostics Nichols Institute of Valencia
For test information, please call Client Services at 800-421-4449.

San Francisco Web Design & Database